ITCA 650 (exenatide in DUROS)

DRUG2 trials

Sponsors

Intarcia Therapeutics

Conditions

Type 2 Diabetes

Phase 1

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

CompletedNCT01798264

Intarcia TherapeuticsType 2 Diabetes

Start: 2009-02-28End: 2009-05-31Updated: 2013-05-17

Phase 3

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

TerminatedNCT01785771

Intarcia TherapeuticsType 2 Diabetes

Start: 2013-05-31End: 2018-01-31Target: 100Updated: 2019-03-07

Related Papers

A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.

2013-04-0814 citations